Pharmafile Logo
Pharmafocus logo
Advanced Search

keytruda

Showing 15 posts of 134 posts found.

shutterstock_291014192

Asia-Pacific NSCLC market to more than double to $6.2bn by 2023

March 21, 2017
Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo

New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …

News
merck_and_co

MSD’s Keytruda notches another FDA approval in Hodgkin lymphoma

March 15, 2017
Research and Development, Sales and Marketing Hodgkin lymphoma, MSD, keytruda

MSD, otherwise known as Merck in North America, continues to score indication successes with Keytruda, this time in Hodgkin lymphoma. …

News
shutterstock_141299494

Immunotherapy: The three major treatments that are changing cancer prognoses

March 13, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Cancer, MSD, Roche, immunotherapy, keytruda, oncology, opdivo, tecentriq

The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, …

Feature
keytruda1

NICE knocks back MSD’s Keytruda for lung cancer indication

February 28, 2017
Research and Development, Sales and Marketing MSD, NICE, NSCLC, keytruda

MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by the National Institute of Health and Care Excellence (NICE) for …

News
keytruda3-web

MSD aims to get the jump on BMS treating bladder cancer

February 6, 2017
Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, MSD, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its …

News

FDA clears Opdivo to treat most common form of bladder cancer

February 6, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …

News

BMS receives $625 million patent settlement boost from Merck

January 23, 2017
Sales and Marketing BMS, MSD, Merck, keytruda, opdivo

Bristol-Myers Squibb were in desperate need of releasing good news after the brief announcement that it would no longer be …

News

MSD and Lilly announce immuno-oncology collaboration

January 11, 2017
Medical Communications, Research and Development Eli Lilly, Lartruvo, MSD, keytruda, lilly

MSD, known as Merck in North America, and Eli Lilly have announced the expansion of their existing immuno-oncology collaboration. The …

News
merck_and_co

MSD looks to jump the gun with combination immunotherapy application

January 11, 2017
Research and Development, Sales and Marketing AstraZeneca, BMS, MSD, Roche, immunotherapy, keytruda

MSD, known as Merck in North America, has launched a bold move by filing Keytruda, and being accepted, for Priority …

News
merckincweb1

NICE approves MSD’s Keytruda for new cancer indication

December 1, 2016
Medical Communications, Sales and Marketing MSD, NICE, keytruda

The National Institute of Health and Care Excellence (NICE) has announced its recommendation of MSD’s immunotherapy drug Keytruda (pembrolizumab) for …

News
merck_and_co

MSD’s Keytruda given first FDA approval for first line treatment

October 25, 2016
Manufacturing and Production BMS, MSD, NSCLC, keytruda, opdivo

MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with …

News
merck_incweb

MSD’s Keytruda early success ends trial early

October 24, 2016
Sales and Marketing MSD, Merck, Roche, keytruda, opdivo, tecentriq

MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer …

News
opdivo_1_1

Failure for BMS’ Opdivo in lung cancer trial

October 10, 2016
Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq

Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …

News
msd_merck_night_building

MSD’s Keytruda twice as successful against standard therapy for lung cancer

October 10, 2016
Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda

MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …

News
1511671_logo_1456919640

Merck’s Keytruda suffers rejection at hands of NICE

October 5, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda

NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025